drugset
drugset / Trial / NCT00358930

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT00358930 ↗

Phase 2 Completed 60 enrolled ArQule, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).

Timeline

Start
2006-07
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LAPACHONE Small molecule — —

Indications

head and neck neoplasm squamous cell carcinoma